CASP8

Across TCGA pan-cancer cohorts, CASP8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CASP8 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CASP8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CASP8 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where CASP8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.587	0.858	.007	14	view →
LUAD	DFS	Quartile	All	0.401	0.853	.016	8	view →
GBM	DFS	Median	All	0.641	0.859	.001	8	view →
HNSC	DFS	Median	IV	0.680	0.902	.017	5	view →
LSCC	DFS	Median	All	0.907	0.969	.023	3	view →
PDAC	OS	Tertile	All	0.645	0.484	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CASP8–CCRCC (DFS)

Open the CCRCC breakdown →